The cell dissociation market is projected to grow from USD 0.6 billion in 2023 to USD 1.4 billion by 2028 at a CAGR of 17.8%. The growth in this market is attributed to expanding pool of operational entities in the market and established protocols for using enzymatic dissociation agents are key contributors to market growth. Moreover, the growth opportunities in emerging markets are expected to provide growth opportunities for players in the cell dissociation market during the forecast period.
The cell dissociation market is highly consolidated and is dominated by various players. The major players operating in this market are Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Corning Incorporated (US), Becton, Dickinson and Company (US), STEMCELL Technologies (Canada), PromoCell GmbH (Germany), Miltenyi Biotec (Germany), ATCC (US), HiMedia Laboratories (India), PAN-Biotech (Germany), CellSystems GmbH (Germany), AMSBIO (England), Neuromics (US), VitaCyte, LLC. (US), ALSTEM (US), Biological Industries (Israel), Gemini Bio (US), Innovative Cell Technologies, Inc. (US), Central Drug House (P) Ltd. (India), Worthington Biochemical Corporation (US), Capricorn Scientific (Germany), Abeomics (US), and Genlantis, Inc. (US).
To know about the assumptions considered for the study download the pdf brochure
Thermo Fishers Scientific (US)
This company offers both enzymatic and non-enzymatic cell dissociation products through the Biosciences segment of its Life Sciences business division. The company has a strong geographic footprint and operates in more than 150 countries across North America, Europe, Latin America, and Asia. The company’s dominant position in the cell culture industry accounts for its strength in the cell dissociation segment. Thermo Fisher has witnessed a strong demand for its Biosciences products in the past two years and is expanding its capabilities within this segment to address customer needs. In September 2022, the company announced the expansion of cell culture media manufacturing to strengthen its bioprocess manufacturing capacity.
Danaher Corporation (US)
Danaher conducts its business through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences business segment offers products under the Cytiva, Pall Corporation, Beckman Coulter, and Leica Microsystems brands. Robust capital investments in Pall Corporation and Cytiva are anticipated to offer the company a competitive edge in the cell dissociation market. The acquisition of Cytiva in 2020 strengthened Danaher’s brand establishment, contributing to the latter’s prominence in the cell dissociation industry. Additionally, in September 2022, Danaher announced the merger of Pall Corporation and Cytiva to broaden its bioprocess portfolio. This acquisition is expected to open new avenues of business expansion for Danaher.
Corning Incorporated (US)
Corning Incorporated provides an extensive range of cell dissociation products across enzymatic and non-enzymatic dissociation. The company offers cell dissociation products through the Cell Culture Products segment within the Life Science business division. Corning registered a year-on-year growth of more than 25% in the Cell Culture Products segment in 2021. Despite a comparatively lower year-on-year growth for this segment in 2022, the company is anticipated to maintain its leading position in the cell dissociation market due to a robust product portfolio and developments to strengthen its cell culture business.
Cell Dissociation Market by Product (Trypsin, Papain, DNase, Hyaluronidase, Instruments), Tissue Type (Connective Tissue, Epithelial Tissue), End User (Pharma, Biopharma, Research Institutes), Region- Global Forecast to 2028
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE